Abhinav Sidana, MD, MPH

University of Chicago Medicine and Biological Sciences

Chicago, IL

Abhinav Sidana, MD, MPH, is the Director of Prostate Cancer Focal Therapy, Director of GU Clinical Trials Urology Section, and Associate Professor of Surgery at the University of Chicago Medicine and Biological Sciences in Chicago, IL. Dr. Sidana earned his MD in 2007 from the All India Institute of Medical Sciences in New Delhi. Following this, he pursued a post-doctoral Fellowship in Urology at Johns Hopkins University School of Medicine in Baltimore, Maryland, during which he focused on translational projects relating to cancer immunotherapy and was instrumental in translating the preclinical work for a clinical trial studying cryo-immunotherapy. Subsequently, he completed his urology residency at the University of Cincinnati Medical Center and a urologic oncology fellowship at the National Cancer Institute of the National Institutes of Health. Dr. Sidana’s current clinical practice includes both surgical and non-operative management of prostate, kidney, ureteral, testicular, and bladder cancers. His research interests include functional prostate imaging, image-guided and focal treatments for prostate cancer, and clinical trials on novel treatments for urologic cancers.

Talks by Abhinav Sidana, MD, MPH

Selecting Candidates for Focal Therapy

Posted by Abhinav Sidana, MD, MPH | Apr 2023

Abhinav Sidana, MD, discusses candidate selection for focal therapy, including imaging/biopsy strategies and disease/patient characteristics.

Rationale for Focal Therapy for Prostate Cancer

Posted by Abhinav Sidana, MD, MPH | Mar 2021

Abhinav Sidana, MD, Urologic Surgeon at the University of Cincinnati Medical Center, makes a case for the adoption of focal therapy for patients with prostate cancer as an alternative to radical treatment or active surveillance. To show how incorporating focal therapy into the treatment paradigm could help personalize care, Dr. Sidana highlights three points: the shortcomings of a treatment strategy that involves only dichotomous options; the increasing need for treatment tailored to the biology of prostate cancer; and how the advent of visible prostate cancer due to next-generation imaging has altered treatment approaches. Following this, Dr. Sidana takes questions from E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, about related topics, including the role of micro-ultrasound in the disease space and the patient followup process.